Regulatory News
Navigating the evolving landscape of drug development and regulatory compliance can be complex and challenging. From FDA guidance updates to international regulatory changes, staying informed is critical for researchers, biotech innovators, and pharmaceutical professionals. This page brings you a curated list of the most important news in drug development regulation, highlighting updates from the FDA, EMA, and other regulatory bodies around the world
Regulatory News
Navigating the evolving landscape of drug development and regulatory compliance can be complex and challenging. From FDA guidance updates to international regulatory changes, staying informed is critical for researchers, biotech innovators, and pharmaceutical professionals. This page brings you a curated list of the most important news in drug development regulation, highlighting updates from the FDA, EMA, and other regulatory bodies around the world.
The FDA’s new draft guidance on genome editing safety marks a significant step toward more standardized, data-driven evaluation of gene therapies. With next-generation sequencing (NGS) at the core, the guidance outlines clear expectations for assessing off-target effects, genomic integrity, and rare editing events, providing sponsors with a more defined regulatory path for IND and BLA submissions.
The FDA is clarifying its flexible approach to chemistry, manufacturing, and control (CMC) requirements for cell and gene therapies, helping sponsors accelerate development and prepare for Biologics License Applications while maintaining rigorous standards for safety, quality, purity, and potency.
The FDA’s new guidance on therapeutic protein biosimilars emphasizes rigorous analytical assessment as the foundation for demonstrating similarity. Developers must focus on physicochemical, functional, and quality attributes to streamline regulatory approval and reduce clinical study requirements.
Explore the FDA’s new Plausible Mechanism Pathway and how it compares to accelerated approval, expedited programs, and other regulatory routes for rare disease therapies.
The FDA released three new draft guidances to streamline cell and gene therapy development. The documents outline innovative trial designs for small populations, expedited pathways for serious conditions, and improved postapproval methods for monitoring long-term safety and efficacy...
When a gene therapy company needed to verify plasmid identity, purity, and integrity for an IND submission, Avance Biosciences delivered a validated NGS-based solution. The assay enabled low-level variant detection and trace contaminant analysis, supporting FDA compliance and lot release.
Avance delivers end-to-end NGS workflow compliance with a robust framework for data integrity, pipeline validation, and audit readiness—tailored for regulated environments...
The FDA is embracing AI to streamline drug reviews, aiming for full implementation by June 2025. Following a successful pilot, this move could fast-track therapy approvals and reduce administrative tasks for scientists...
The FDA is phasing out animal testing for monoclonal antibodies and other drugs, turning to AI, lab-grown human tissues, and global safety data to streamline development, cut costs, and improve patient safety...
Avance Biosciences offers CLIA-compliant testing services to ensure accurate, reliable data throughout drug development. From biomarker validation to regulatory support, our expertise helps biopharmaceutical companies advance clinical trials and bring innovative biologic treatments to market with confidence...
